Stray Dog

HIMS pay row drives a 15% two-day drop before Q1

  • Bad news: After media coverage of CEO Dudum's $22.96 million 2025 pay, shares fell about 15% in two days to $26.33.
  • Bad news: Short sellers held 37.85% of the float, and insiders sold $5.5 million over three months without buying.
  • Mixed: The consensus target of about $32 implies 21% upside, but targets range from $21 to $35.
Read the full notes

Analyst consensus

The sell side is framing the stock around a 'Lilly lifeline vs Amazon ambush' narrative. JPMorgan has the highest target at $35 and Morgan Stanley the lowest at $21, with the consensus at about $32. At the current price of $26.33, the consensus implies 21% upside.

CEO compensation

CEO Andrew Dudum's total pay for 2025 was $22.96 million, against $84,402 for the median employee, a gap of 272 times. After the media amplified the story, the shares fell on 29-30 Apr (-4.95%, then -5.66%), pulling back from $31 to $26.33, a 2-day drop of about 15%. Annual revenue was $2.35 billion, up 59%, and most of the pay is equity incentives. The shareholder vote on pay on 11 Jun is approaching.

Short interest

FINRA data as of 15 Apr: short sellers held 37.85% of the float (versus 36.3% on 31 Mar). Shorts added slightly during the rebound. Over the past 3 months insiders have sold a cumulative $5.5 million and bought none.

Upcoming catalyst

Q1 results on 11 May after the close. The options market implies a move of more than 12%. Key things to watch: the trend in subscriber growth, the effect of the shift to branded drugs on gross margin, and what management says about the timeline for peptide drugs.